Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

EXTON, Pa., Feb. 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2010.

In 2010, we:

  • Achieved a record $439 million in annual net product sales, including $177 million in net sales of Cinryze® (C1 esterase inhibitor [human]);
  • Attained non-GAAP adjusted net income of $157 million, representing 88 percent growth over the prior year; GAAP net income reached $126 million;
  • Delivered positive cash flows from operations of $194 million; and
  • Improved working capital to $561 million as of December 31, 2010, including cash, cash equivalents and short-term investments of $505 million;

  • Net sales were $121.6 million and $439.0 million for the fourth quarter and year ended December 31, 2010, respectively, as compared to $87.8 million and $310.4 million in the comparative periods of 2009, respectively.  This represents 38 percent growth in the fourth quarter and 41 percent growth for the year in net product sales.

    "2010 was an outstanding year for ViroPharma, and by focusing on the needs of our patients we were able to achieve excellent financial results," stated Vincent Milano, ViroPharma's chief executive officer.  "I'm proud of the work that our team did in 2010 to improve the lives of patients suffering from life threatening illnesses including hereditary angioedema.  Our work in 2011 will continue to build upon these efforts to foster brand loyalty by listening and responding to the needs of our patients, enhancing our patient support tools, providing an additional mode of administration of Cinryze, and globalizing the Cinryze experience.  On that topic, I am pleased to announce that we have recently submitted our responses to our European MAA Day 180 questions, and remain confident in our ability to gain Eur
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
    (Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
    (Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
    (Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
    Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
    ... Members of IEEE , the world,s ... of engineering sciences and technology with medicine and ... a collaborative approach to healthcare that integrates ideas ... systems biology, neuro-engineering, among other disciplines, IEEE and ...
    ... Dec. 7, 2010 Cellectis bioresearch, the specialist in ... announced that it has signed a non-exclusive agreement with ... This license allows Cellectis bioresearch to incorporate these proteins ... offering of genome engineering tools. Luc ...
    ... out completely, it would be more than six feet long. It,s ... of your cells, but that,s exactly how it works. ... how DNA is packaged in cells, and have found strong indications that ... comprised mostly of an amino acid molecule called a histone influences ...
    Cached Biology Technology:IEEE: On a Mission to Make Healthcare Personal, Again 2IEEE: On a Mission to Make Healthcare Personal, Again 3IEEE: On a Mission to Make Healthcare Personal, Again 4Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins 2Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins 3UNC-led team tests commonly used antibodies 2
    (Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
    (Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
    Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... Small Grains Breeding Program is developing a new type ... hulless barley offers producers an alternative grain for both ... , The price for winter barley has declined since ... of the region's cropping system, growers stopped producing it ...
    ... the University of Chicago have found that a recently discovered ... be active only in the nucleus -- also occurs near ... possibly many kinds of proteins, providing a novel target for ... the 8 April 2005 issue of the journal Cell, answers ...
    ... regions worldwide where 75 percent of the planet's most ... just 2.3 percent of the Earth's surface (roughly equivalent ... states). This habitat originally covered 15.7 percent of the ... and Australia combined. The new analysis shows that an ...
    Cached Biology News:New winter hulless barley has high protein 250-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 250-year-old Mystery Solved: Protein Tags Regulate Key Ion Channel 3Biodiversity hotspots identify conservation priorities 2Biodiversity hotspots identify conservation priorities 3Biodiversity hotspots identify conservation priorities 4Biodiversity hotspots identify conservation priorities 5
    ... nmol (individual) with sequence siTrio siRNA ... to your target gene of interestis our most ... more than 75% knockdown of your target gene ... for transfection and confirmation of optimal transfection with ...
    The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
    ... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
    ... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
    Biology Products: